Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck(University of Rochester Medicine), Allen Radin(Regeneron (United States)), Richard Kao(Eisai (Japan)), Jennifer D. Hamilton(Regeneron (United States)), Marius Ardeleanu(Regeneron (United States)), Mayte Suárez‐Fariñas(Rockefeller University), Neil M.H. Graham(UK Dementia Research Institute), Neil Stahl(Arthritis and Rheumatism Associates), George D. Yancopoulos(Regeneron (United States)), Diamant Thaçi(University of Lübeck), Melissa Hager(Regeneron (United States)), Gianluca Pirozzi(Sanofi (United States)), Eric L. Simpson(Oregon Health & Science University), Steven P. Weinstein(Regeneron (United States)), Ross E. Rocklin(Sanofi (United States)), Haobo Ren(Regeneron (United States)), Thomas Bieber(CK-CARE), Jeffrey E. Ming(Sanofi (United States)), Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai)
Cited by 1,418
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k